Related Experiment Video
Updated: Feb 2, 2026

Study of the DNA Damage Checkpoint using Xenopus Egg Extracts
Published on: November 5, 2012
Neuromuscular complications of immune checkpoint inhibitors
1Sorbonne université, Inserm, CNRS, UMR S 1127, institut du cerveau et de la moelle épinière, ICM, AP-HP, hôpitaux universitaires La Pitié Salpêtrière - Charles Foix, service de neurologie 2-Mazarin, 75013 Paris, France; OncoNeuroTox Group, Center for Patients with Neurological Complications of Oncologic Treatments, Hôpitaux Universitaires Pitié-Salpetrière-Charles Foix et Hôpital Percy, 75013 Paris, France.
Abstract:
Immune checkpoint inhibitors have been increasingly used in patients with various cancers. Despite favourable oncological outcomes these treatments have also been associated with immune-related adverse events. Neurological irAE are rare but potentially severe and neuromuscular complications are the most common. This is a new group of neurologic complications of systemic anticancer therapies, often responsive to immune-modulating therapies. Early recognition and treatment are crucial for timely improvement of functional outcome and requires a multidisciplinary approach.
Insights
Immune checkpoint inhibitors (ICIs) can cause rare but severe neurological immune-related adverse events (irAEs), primarily affecting the neuromuscular system. Early multidisciplinary recognition and treatment with immune-modulating therapies are crucial for better patient outcomes.
Area of Science:
- Oncology
- Neurology
- Immunology
Background:
- Immune checkpoint inhibitors (ICIs) are widely used cancer treatments.
- While effective, ICIs can cause immune-related adverse events (irAEs).
- Neurological irAEs are uncommon but serious complications of ICIs.
Purpose of the Study:
- To highlight the occurrence and characteristics of neurological irAEs.
- To emphasize the importance of early diagnosis and management.
- To underscore the need for a multidisciplinary approach in managing these events.
Main Methods:
- Review of existing literature on neurological irAEs associated with ICIs.
- Analysis of clinical presentations and treatment responses.
- Synthesis of information regarding diagnostic challenges and therapeutic strategies.
Main Results:
- Neuromuscular complications are the most frequent type of neurological irAE.
- These events represent a distinct category of neurologic complications from systemic anticancer therapies.
- Many neurological irAEs show responsiveness to immune-modulating treatments.
Conclusions:
- Neurological irAEs are rare but severe adverse events associated with ICIs.
- Prompt identification and intervention are critical for improving functional outcomes.
- A collaborative, multidisciplinary approach is essential for optimal patient care.
Related Concept Videos
The Spindle Assembly Checkpoint
Many proteins function together to control the spindle assembly checkpoint. Mutations affecting these proteins may allow cells to proceed into anaphase prematurely, resulting in the...
Eukaryotic Transcription Inhibitors
Eukaryotic transcription inhibitors usually contain two distinct domains, a...
Hemodialysis II: Procedure and Complications
What is the Immune System?
The Neuromuscular Junction
Pneumonia III: Complications and Assessment

